APP and Alzheimer disease: DNA methylation patterns, such as hypermethylation of the APP promoter in AD, are emerging as non-invasive biomarkers detectable in peripheral blood or cerebrospinal fluid, offering the potential for early and accurate diagnosis [86,87].